Reck M - Search Results

1

Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.

Nitschkowski D, Marwitz S, Kotanidou SA, Reck M, Kugler C, Rabe KF, Ammerpohl O, Goldmann T. Nitschkowski D, et al. Among authors: reck m. Clin Epigenetics. 2019 Nov 12;11(1):157. doi: 10.1186/s13148-019-0770-6. Clin Epigenetics. 2019. PMID: 31718698 Free PMC article.

2

Management of non-small-cell lung cancer: recent developments.

Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Reck M, et al. Lancet. 2013 Aug 24;382(9893):709-19. doi: 10.1016/S0140-6736(13)61502-0. Lancet. 2013. PMID: 23972814 Review.

3

[New developments in treatment of non-small cell lung cancer].

Reinmuth N, Gröschel A, Reck M. Reinmuth N, et al. Among authors: reck m. Pneumologie. 2013 Nov;67(11):634-8. doi: 10.1055/s-0033-1344793. Epub 2013 Nov 6. Pneumologie. 2013. PMID: 24198238 Free article. Review. German.

4

Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissues.

Lang DS, Marwitz S, Heilenkötter U, Schumm W, Behrens O, Simon R, Reck M, Vollmer E, Goldmann T. Lang DS, et al. Among authors: reck m. Pathol Oncol Res. 2014 Jul;20(3):727-32. doi: 10.1007/s12253-014-9753-2. Epub 2014 Mar 9. Pathol Oncol Res. 2014. PMID: 24610082 Free article.

5

The tissue is the issue: improved methylome analysis from paraffin-embedded tissues by application of the HOPE technique.

Marwitz S, Kolarova J, Reck M, Reinmuth N, Kugler C, Schädlich I, Haake A, Zabel P, Vollmer E, Siebert R, Goldmann T, Ammerpohl O. Marwitz S, et al. Among authors: reck m. Lab Invest. 2014 Aug;94(8):927-33. doi: 10.1038/labinvest.2014.79. Epub 2014 Jun 16. Lab Invest. 2014. PMID: 24933424 Free article.

6

Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.

Reck M, Heigener D, Reinmuth N. Reck M, et al. Expert Rev Clin Pharmacol. 2014 Sep;7(5):579-90. doi: 10.1586/17512433.2014.945430. Expert Rev Clin Pharmacol. 2014. PMID: 25119062 Review.

7

Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.

Heigener D, Reck M. Heigener D, et al. Among authors: reck m. Expert Rev Anticancer Ther. 2015 Jan;15(1):69-83. doi: 10.1586/14737140.2015.957187. Epub 2014 Sep 9. Expert Rev Anticancer Ther. 2015. PMID: 25199617 Review.

8

[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients].

Reinmuth N, Heigener D, Goldmann T, Watermann I, Reck M. Reinmuth N, et al. Among authors: reck m. Pneumologie. 2014 Sep;68(9):619-23. doi: 10.1055/s-0034-1377927. Epub 2014 Sep 9. Pneumologie. 2014. PMID: 25203821 Free article. Clinical Trial. German.

9

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.

Gaber R, Watermann I, Kugler C, Reinmuth N, Huber RM, Schnabel PA, Vollmer E, Reck M, Goldmann T. Gaber R, et al. Among authors: reck m. Diagn Pathol. 2014 Sep 17;9:165. doi: 10.1186/s13000-014-0165-0. Diagn Pathol. 2014. PMID: 25227424 Free PMC article.

10

Targeting of MEK in lung cancer therapeutics.

Heigener DF, Gandara DR, Reck M. Heigener DF, et al. Among authors: reck m. Lancet Respir Med. 2015 Apr;3(4):319-27. doi: 10.1016/S2213-2600(15)00026-0. Epub 2015 Mar 20. Lancet Respir Med. 2015. PMID: 25801412 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters